Journal Article10.1002/OBY.22969
Antidepressant Medications and Weight Change: A Narrative Review
Hartej Gill,Hartej Gill,Barjot Gill,Sabine El-Halabi,David Chen-Li,Orly Lipsitz,Joshua D. Rosenblat,Joshua D. Rosenblat,Tamsyn E Van Rheenen,Tamsyn E Van Rheenen,Nelson B. Rodrigues,Rodrigo B. Mansur,Rodrigo B. Mansur,Amna Majeed,Leanna M.W. Lui,Flora Nasri,Yena Lee,Yena Lee,Roger S. McIntyre +18 more
116
TL;DR: Current findings suggest the role of histamine and serotonin off‐target appetite‐promoting pathways in adverse weight‐gain effects and controlling for undesired weight effects is an important consideration for the selection of antidepressants.
read more
Abstract: Antidepressant medications are the first-line treatment option for moderate to severe major depressive disorder. However, most antidepressants have numerous documented adverse events, including cardiometabolic effects and weight gain, which are major public health concerns. Antidepressant agents provide varying risk of associated weight gain, including significant within-class differences. Some agents, such as mirtazapine, show significant levels of weight gain, while others, such as bupropion, demonstrate weight-loss effects. Current findings suggest the role of histamine and serotonin off-target appetite-promoting pathways in adverse weight-gain effects. Therefore, controlling for undesired weight effects is an important consideration for the selection of antidepressants.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Diagnosis and Drug Treatment of Psychiatric Disorders
TL;DR: Drs Klein and Davis, exceptionally well-qualified experts on the psychoactive drugs and their judicious use, have achieved their goal of satisfying the need of prescribing physicians.
318
GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors.
Rok Cerne,Arnold S. Lippa,Michael M. Poe,Jodi L. Smith,Xiaoming Jin,Xingjie Ping,Lalit K. Golani,James M. Cook,Jeffrey M. Witkin +8 more
TL;DR: A review of the new GABAkines in this paper focuses on the new compounds that are presently being developed and commercialized include several neuroactive steroids (an all-opregnanolone formulation (brexanolone), an allopregnolone prodrug (LYT-300), Sage-324, zuranolone, and ganaxolone), the α2/3-preferring GABAkine, KRM-II-81, and the α 2/3/5-prefering GABA kine PF-0637
70
Weight gain during long-term treatment of obsessive-compulsive disorder
Giuseppe Maina,Virginio Salvi,Umberto Albert,Filippo Bogetto +3 more
- 01 Jan 2003
TL;DR: In this article, the effect of extended anti-depressant treatment on weight has been poorly investigated, and also unknown is whether different compounds have differential effects, and the aim of the present study was to assess changes in weight in obsessive-compulsive disorder patients treated for 2.5 years with clomipramine or selective serotonin reuptake inhibitors.
52
Non-Alcoholic Fatty Liver Disease (NAFLD) and Potential Links to Depression, Anxiety, and Chronic Stress.
Sue Shea,Sue Shea,Christos Lionis,Chris Kite,Chris Kite,Chris Kite,Lou Atkinson,Lou Atkinson,Surinderjeet S. Chaggar,Harpal S. Randeva,Harpal S. Randeva,Ioannis Kyrou +11 more
TL;DR: In this paper, a review discusses published evidence in relation to associations of depression, anxiety, stress, and impaired health-related quality of life with NAFLD and metabolic syndrome.
49
Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis
TL;DR: In this article , the prevalence of type 2 diabetes mellitus (T2DM), impaired fasting glucose (IFG), as well as general and abdominal obesity in patients with bipolar disorder (BD) was assessed.
48
References
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.
Lakshmi N. Yatham,Sidney H. Kennedy,Sagar V. Parikh,Ayal Schaffer,Serge Beaulieu,Martin Alda,Claire O'Donovan,Glenda MacQueen,Roger S. McIntyre,Verinder Sharma,Arun V. Ravindran,L. Trevor Young,Roumen Milev,David J. Bond,Benicio N. Frey,Benjamin I. Goldstein,Beny Lafer,Boris Birmaher,Kyooseob Ha,Willem A. Nolen,Michael Berk,Michael Berk +21 more
TL;DR: The Canadian Network for Mood and Anxiety Treatments published guidelines for the management of bipolar disorder in 2005, with updates in 2007 and 2009, and this third update, in conjunction with the International Society for Bipolar Disorders, reviews new evidence and is designed to be used in conjunctionWith the previous publications.
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder Section 3. Pharmacological Treatments
Sidney H. Kennedy,Raymond W. Lam,Roger S. McIntyre,S. Valérie Tourjman,Venkat Bhat,Pierre Blier,Mehrul Hasnain,Fabrice Jollant,Anthony J. Levitt,Glenda MacQueen,Shane McInerney,Diane McIntosh,Roumen Milev,Daniel J. Müller,Sagar V. Parikh,Norma L. Pearson,Arun V. Ravindran,Rudolf Uher +17 more
TL;DR: Evidence-based pharmacological treatments are available for first-line treatment of major depressive disorder and for management of inadequate response, however, given the limitations of the evidence base, pharmacological management of MDD still depends on tailoring treatments to the patient.
1K
Pharmacological profile of antidepressants and related compounds at human monoamine transporters.
TL;DR: Using radioligand binding assays, the equilibrium dissociation constants (KD's) for 37 antidepressants, three of their metabolites, some mood stabilizers, and assorted other compounds for the human serotonin, norepinephrine, and dopamine transporters are determined to help predict some possible adverse effects and drug-drug interactions of antidepressants and related compounds.
956
H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs
Wesley K. Kroeze,Sandra J. Hufeisen,Beth A. Popadak,Sean Michael Renock,Seanna Steinberg,Paul Ernsberger,Karu Jayathilake,Herbert Y. Meltzer,Bryan L. Roth +8 more
TL;DR: It is recommended that the next generation of atypical antipsychotic drugs be screened to avoid H1-histamine receptors, which are known to induce weight gain with chronic use.
796
Tricyclic antidepressant pharmacology and therapeutic drug interactions updated
TL;DR: New data on the pharmacology of tricyclic antidepressants, their affinities for human cloned CNS receptors and their cytochrome P450 enzyme inhibition profiles, allow improved deductions concerning their effects and interactions and indicate which of the TCAs are the most useful.